Literature DB >> 35443294

Reducing distal pancreatectomy by posterolateral approach for splenectomy in the surgical management of ovarian cancer.

Sang-Yoon Park1.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35443294      PMCID: PMC9024189          DOI: 10.3802/jgo.2022.33.e48

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN: 2005-0380            Impact factor:   4.756


× No keyword cloud information.
  5 in total

1.  Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.

Authors:  K S Tewari; J J Java; R N Eskander; B J Monk; R A Burger
Journal:  Ann Oncol       Date:  2015-10-20       Impact factor: 32.976

2.  Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

Authors:  Robert E Bristow; Rafael S Tomacruz; Deborah K Armstrong; Edward L Trimble; F J Montz
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

3.  Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis.

Authors:  Min-Hyun Baek; Eun Young Park; Hyeong In Ha; Sang-Yoon Park; Myong Cheol Lim; Christina Fotopoulou; Robert E Bristow
Journal:  J Clin Oncol       Date:  2022-02-21       Impact factor: 50.717

4.  Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.

Authors:  Myong Cheol Lim; Heong Jong Yoo; Yong Jung Song; Sang Soo Seo; Sokbom Kang; Sun Ho Kim; Chong Woo Yoo; Sang Yoon Park
Journal:  J Gynecol Oncol       Date:  2017-07       Impact factor: 4.401

5.  Predictors of postoperative pancreatic fistula after splenectomy with or without distal pancreatectomy performed as a component of cytoreductive surgery for advanced ovarian cancer.

Authors:  Kyoko Nishikimi; Shinichi Tate; Ayumu Matsuoka; Satoyo Otsuka; Makio Shozu
Journal:  J Gynecol Oncol       Date:  2022-01-20       Impact factor: 4.756

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.